Drug Profile


Alternative Names: 15(S)-HETE; 15(S)-hydroxyeicosatetraenoic acid; 15-HETE; AL-12959; Dry eyes therapy - Alcon; PROCALYX

Latest Information Update: 03 Jul 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alcon
  • Class Antineoplastics; Eye disorder therapies; Small molecules; Vasodilators
  • Mechanism of Action Mucin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Dry eyes

Most Recent Events

  • 03 Jul 2007 No development reported - Phase-II for Dry eyes in European Union (unspecified route)
  • 03 Jul 2007 No development reported - Phase-III for Dry eyes in USA (unspecified route)
  • 03 Jul 2007 No development reported - Preclinical for Dry eyes in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top